OncoVista Innovative Therapies, Inc. (OVIT)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Jan 15, 2026
OncoVista Innovative Therapies Company Description
OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers.
The company’s product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer.
The company was founded in 2004 and is based in San Antonio, Texas.
OncoVista Innovative Therapies, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Alexander Weis |
Contact Details
Address: 14785 Omicron Drive San Antonio, Texas 78245 United States | |
| Phone | 210-677-6000 |
| Website | oncovista.com |
Stock Details
| Ticker Symbol | OVIT |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US68232J1051 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander L. Weis Ph.D. | Chairman, Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer and Secretary |